UnitedHealth Group Inc (UNH)

The health sector is poised to rally after a rough year. UNH is a good company though he prefers Humana.

His largest position. A quality, defensive names that benefits from employment growth. Also, what will the weight-loss drug do for them? Smart managers. A permanent compounder.

Rallied 5% in Q3. Had come back after Covid and good for them, but he prefers Humana (he owns).

Likes the diversified business model. Leader. Decent valuation at 19x forward PE, with 12% earnings growth. Past year has seen a rotation out of managed care into more exciting pharma names. Stable revenues, downturn-resilient. Aging US demographics will benefit.

Very well manged company - best in sector.
Does not own shares.
Investing in other areas in healthcare sector.
Share price falling on concerns for pricing power.
Good long term investment. 

Likes their fundamentals as well as the healthcare sector, a sector which has been rallying.

Likes it, with the economy opening up and the company securing some price increases. Not a home run stock. You're looking at returns of 10-15% per annum.

He owns many healthcare names including UHN, but isn't excited about these names because they have lost momentum. Their CFO has warned of higher costs, which has lowered the bar a today. Earnings beat today, yes, but the bar is very low.

A core holding. It performed well, though down 8% this year. Revenue is up 13%, though costs up 16%. Their medical ratio is at 83% vs. 81% last year, but in line with the street. Shares are jumping today on earnings.

Shares are down 9% YTD, but is rallying 8% today on strong earnings. Has always liked this stalwart in healthcare.

Massive insurance company with very strong business.
Mostly benefiting from secular growth.
16% compounding rate in earnings. 
Current share price presenting great opportunity to buy.
Excellent long term hold.

Down 7% today after UNH warned of higher costs ahead. The sell-off is an over-reaction. Of course, surgeries cost more because hospitals are supply-constrained so that slows growth. Also, insurers can reprice each year, raising prices. This will work itself out.

Trading way up at its FMV, and usually that's it for the stock. Not much more upside. Buy CNC instead.

It is a defensive stock that is executing very well as a large health insurance company with its own physician networks and clinics. It administers Medicare and Medicaid and has a clear runway for double digit growth. Yield is 1.3%

His preference in the space. It's insulated from retail exposure, which is impacted with more prescriptions being filled online. Benefits from trend to value-based care, which pays for patient outcomes rather than services provided.